Barclays raised the firm’s price target on CytomX Therapeutics (CTMX) to $10 from $8 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics participates in a conference call with Cantor
- CytomX Therapeutics initiated with a Buy at Guggenheim
- CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler
- CytomX Therapeutics price target raised to $8 from $6 at Barclays
- CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target